Representations, Beliefs and Attitudes Towards Hypnosis in Patients Followed for Colorectal Cancer
Ontology highlight
ABSTRACT:
DISEASE(S): Cancer Colorectal,Colorectal Neoplasms,Hypnosis, Animal
PROVIDER: 13236 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:RATIONALE: Evaluating the knowledge and attitudes of healthy participants toward a new diet and gene test for colorectal cancer risk may help doctors improve acceptance of colorectal cancer screening.
PURPOSE: This clinical trial is studying the knowledge and attitudes of healthy participants toward genetic and environmental risk assessment for colorectal cancer.
| 2011105 | ecrin-mdr-crc
Project description:Interventions: Group 1: The EC@T-project consists of three substudies: two qualitative and one quantitative study. In all three studies there will be two sample groups, providers and chronically ill patients (see fulfilling one of the diagnoses). First, within the qualitative study we will interview the attitudes of patients and providers and we are planning to generate items for the EC@T questionnaire. Then all participants will fill out the questionnaire.
Primary outcome of the project is to develop the EC@T questionnaire based on interview data and analysis of literature. aim: measurement of attitudes towards eCommunication of providers and chronically ill patients.
Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other
| 2430027 | ecrin-mdr-crc
Project description:<p>Whole genome sequencing (WGS) and whole exome sequencing (WES) services are currently available to and being utilized by physicians and their patients in both research and clinical settings, and recently to anyone in the general public via direct-to-consumer companies. But the widespread availability and use of WGS and WES in the practice of clinical medicine is imminent. In the very near future, sequencing of individual genomes will be inexpensive and ubiquitous, and patients will be looking to the medical establishment for interpretations, insight and advice to improve their health. Developing standards and procedures for the use of WGS information in clinical medicine is an urgent need, but there are numerous obstacles related to integrity and storage of WGS data, interpretation and responsible clinical integration.</p> <p>The MedSeq Project is an exploratory trial of WGS in clinical medicine. At the conclusion of this study, we will have helped create innovative protocols and novel outcome measures that can be applied safely in future large-scale multi-site randomized clinical trials with larger numbers of physicians from broad specialties and with more economically and ethnically diverse patients. Together with our colleagues from across the nation through the U01 consortium formed as a result of this funding from the NIH, we will have invented a process of implementation and evaluation whereby the fruits of the Human Genome Project can be applied for the first time to the daily practice of medicine for the betterment of human health.</p> <p>The objectives of the MedSeq Project are to: <ol> <li>Recruit, consent and enroll 2 study groups:</li> <ol type="a"> <li>10 primary care physicians and 100 of their healthy middle-aged patients </li> <li>10 cardiologists and 100 of their patients with cardiomyopathy.</li> </ol> <li>Randomize each study group to receive standard of care versus standard of care plus WGS.</li> <li>Monitor the entire protocol for subject safety.</li> <li>Only half the enrolled patients were selected for sequencing. Fifty subjects were selected from the primary care cohort and fifty were selected from the cardiomyopathy cohort. Whole genome sequencing was performed at 30x coverage in Illumina's CLIA-certified laboratory on these 100 individuals.</li> <li>Generate and optimize an algorithm for interpreting WGS data covering the spectrum of human genetic variation, in terms of both previously reported and novel variants likely to influence the health of patients.</li> <li>Create patient reports and provide an interface for communicating clinically relevant genomic information to practicing physicians.</li> <li>Describe physicians' and patients' attitudes toward, and preferences for, the disclosure of WGS results at the start of the study.</li> <li>Evaluate physicians' experiences with receiving and interpreting patients' genetic test results and how they communicate these results to their patients.</li> <li>Explore how patients respond to and use WGS results by administering validated scales of psychological impact, personal utility, and behavioral responses, as well as economic and health outcomes.</li> </ol> </p> <p>Although we do not have a large enough sample size for statistical comparisons of outcomes, we will conduct exploratory comparisons:</p> <p>Exploratory Hypotheses: <ul> <li>Patients who receive WGS results will show equivalent levels of distress compared to patients who receive family history only.</li> <li>Patients with higher genetic literacy and better understanding will report greater satisfaction and less decisional regret.</li> <li>Patients who receive WGS will (a) be more likely to change health behaviors and (b) utilize more health care resources than those who do not receive WGS.</li> </ul> </p>
| phs000958 | dbGaP
Project description:To reveal transcriptome dynamics during adventitious root formation in a coniferous tree, C. japonica, we conducted custom microarry experiments. Three parts from cuttings of easy-to-root clone of C. japonica were collected at eight time points during adventitious root formation. The results revealed major turning points on transcriptome toward adventitious root formation and the expression behavior of genes related to carbohydrate, plant hormone and others suggested the important biological changes for adventitious root formation.
2018-12-25 | GSE102874 | GEO
Project description:Background: Adipose tissue-derived stromal cells (ATSCs) hold great promises in regenerative medicine, due to their easy retrieval, high proliferative capacity, and multi-lineage differentiation potential. In the last decade, several studies have reported the plasticity of ATSCs toward a hepatic fate. Nonetheless, the molecular mechanisms underlying the conversion from a mesenchymal to an epithelial phenotype remain poorly understood. Aim: In this study, we compared the full genome expression profiles of ATSCs cultured for 4 weeks under pro-hepatogenic conditions to undifferentiated ATSCs, in order to depict the molecular events involved in ATSC hepatic transdifferentiation. Methods: Molecular analysis was performed using the Affymetrix human focus arrays. Sets of differentially expressed genes were functionally categorized in order to understand which pathways drive the hepatic conversion and interesting target genes were validated by Q-PCR. Results: We showed that ATSC-derived hepatocyte-like cells activate several genes associated with specific liver functions, including protein metabolism, innate immune response regulation, and biodegradation of toxic compounds. Furthermore, microarray analysis highlighted the downregulation of several transcripts involved in stemness maintenance along with genes associated with a mesenchymal phenotype. Conclusion: Taken together, our data suggest that the in vitro system used in this study drove ATSCs toward a hepatic conversion through a subtle regulation of molecular pathways controlling stem cell properties and lineage commitment that promote mesenchymal-epithelial-transition. Adipose tissue was obtained from 3 patients undergoing partial abdominoplasty. Adipose tissue-derived stromal cells (ATSC) were isolated according to standard procedures, using the in vitro adherence property of these cells. At passage culture 4, ATSC were submitted to an in vitro hepatogenic regimen, consisting of the sequential addition of growth factors. After 1 month of in vitro differentiation, cells were harvested and their transcriptome was compared to control ATSC.
2009-12-14 | E-GEOD-18201 | biostudies-arrayexpress
Project description:Stratification of Leiomyosarcoma molecular subtypes by 3' end RNA-sequencing: Toward precision medicine
| PRJNA194525 | ENA
Project description:Background: Adipose tissue-derived stromal cells (ATSCs) hold great promises in regenerative medicine, due to their easy retrieval, high proliferative capacity, and multi-lineage differentiation potential. In the last decade, several studies have reported the plasticity of ATSCs toward a hepatic fate. Nonetheless, the molecular mechanisms underlying the conversion from a mesenchymal to an epithelial phenotype remain poorly understood. Aim: In this study, we compared the full genome expression profiles of ATSCs cultured for 4 weeks under pro-hepatogenic conditions to undifferentiated ATSCs, in order to depict the molecular events involved in ATSC hepatic transdifferentiation. Methods: Molecular analysis was performed using the Affymetrix human focus arrays. Sets of differentially expressed genes were functionally categorized in order to understand which pathways drive the hepatic conversion and interesting target genes were validated by Q-PCR. Results: We showed that ATSC-derived hepatocyte-like cells activate several genes associated with specific liver functions, including protein metabolism, innate immune response regulation, and biodegradation of toxic compounds. Furthermore, microarray analysis highlighted the downregulation of several transcripts involved in stemness maintenance along with genes associated with a mesenchymal phenotype. Conclusion: Taken together, our data suggest that the in vitro system used in this study drove ATSCs toward a hepatic conversion through a subtle regulation of molecular pathways controlling stem cell properties and lineage commitment that promote mesenchymal-epithelial-transition.
2009-12-15 | GSE18201 | GEO
Project description:Adipose tissue-derived mesenchymal stromal cells (ATSC) hold great promises in regenerative medicine, due to their easy retrieval, their high proliferative capacity, and overall, their multi-lineages differentiation potential. In the last decade, several studies have reported the plasticity of ATSC toward a hepatic fate. Nonetheless, the molecular mechanisms allowing the conversion from a mesenchymal to an epithelial phenotype remain poorly understood. In this study, we investigated the full genome expression profiles of ATSC cultured for 4 weeks under pro-hepatogenic condition in comparison to control ATSC. Sets of differentially expressed genes were then functionally categorized to understand which pathways trigger the hepatic conversion. We showed that ATSC-derived hepatocyte-like cells overexpress sets of genes associated with hepatic functions, including protein metabolism, innate immune response regulation, and biodegradation of toxic compounds. Furthermore, microarray analysis highlighted the downregulation of several transcripts involved in stemness maintenance along with genes associated with the epithelial-mesenchymal-transition. Taken together, these data suggest that in vitro hepatogenic differentiation converts ATSC into immature hepatic cells, functionally related to liver progenitor cells.
2008-12-01 | GSE12399 | GEO
Project description:The crop species Solanum lycopersicum establishes a beneficial root- symbiosis with the widespread group of arbuscular mycorrhizal (AM) fungi. The mycorrhiza establishment leads to a modulation of the plant gene expression which is not restricted to the root compartment but spreads at the organism-wide level. To understand the systemic effect of the fungal presence on the tomato fruit, we performed global transcriptome profiling through RNA-Seq analysis on Moneymaker tomato fruits sampled at the turning ripening stage. Gene expression data were obtained from fruits sampled at 55 days after flowering. Fruits were collected from Funneliformis mosseae colonized plants and from control plants which were fertilized in order to avoid responses related to nutrient deficiency.
2014-04-04 | E-MTAB-2276 | biostudies-arrayexpress
Project description:Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs
| PRJNA524343 | ENA